Late-onset protracted febrile myalgia syndrome successfully treated with colchicine owing to heterozygous MEFV exon 2 variants

Sirs.

Protracted febrile myalgia syndrome (PFMS) is a rare form of familial Mediterranean fever (FMF) characterised by prolonged severe myalgia with high levels of C-reactive protein and serum amyloid A, which sometimes develops with fever, abdominal pain and arthritis associated with FMF. We report a rare case of a Japanese PFMS patient with late disease onset and a good response to colchicine owing to multiple heterozygous MEFV exon 2 variants. A 52-year-old Japanese woman with no family history of autoinflammatory diseases experienced recurrent attacks of exercise-induced severe myalgia in the proximal limbs, lasting for 1-4 weeks every 3 months since the age of 45 years. The attacks were sometimes followed by high fever for the first 1-3 days. She visited an orthopaedic surgeon, and her condition was slightly relieved by treatment with non-steroidal anti-inflammatory drugs (NSAIDs) after every attack. In February 2018, she again experienced prolonged myalgia and was admitted to our department. Laboratory findings during the attack showed normal creatine kinase and aldolase levels and high C-reactive protein levels (6.7 mg/dL). Immunological and serological results and infection-associated assays were all negative. A thoracic-abdominal computed tomography scan revealed a swelling with increased signal intensity in the left biceps femoris muscle. Her symptoms gradually disappeared in 4 weeks with rest and treatment with NSAIDs. Genetic analyses for MEFV and TNFAP3 through direct sequencing revealed heterozygous L110P, E148Q and G304R variants in exon 2 of MEFV. In May 2018, she experienced myalgia with high fever and was administered 1.0 mg/day of colchicine, following which her symptoms gradually disappeared in 7 days; she was eventually diagnosed with PFMS. Since then, she has never experienced attacks and her remission has been maintained for 12 months with continuous colchicine therapy. Our patient had heterozygous L110P, E148Q and G304R variants in MEFV exon 2. Although most previous reports have shown patients with PFMS to harbour heterozygous or homozygous M694V mutations (1, 2), few cases of PFMS associated with homozygous E148Q mutations have been reported (3, 4). To our knowledge, this is the first report of a patient with PFMS associated with multiple heterozygous MEFV exon 2 variants.

Late-onset FMF (LOFMF), defined as FMF onset at >40 years of age (5), is rare (6). Consistent with the features of FMF, most patients with PFMS exhibit early disease onset (2, 7); thus, our case with late-onset PFMS is very rare. The genetic characteristics of patients having FMF in Japan include a lower percentage of MEFV exon 10 mutations with high penetrance and a higher percentage of MEFV exon 2 mutations with low penetrance compared with patients having FMF in Western countries (8). Our previous study indicated that LOFMF patients have a lower percentage of MEFV exon 10 mutations, which contributes to these patients being more common in Japan than in Western countries (8). Therefore, it is important to recognize that PFMS, particularly later-onset PFMS, may be associated with heterozygous MEFV exon 2 variants, even in a country with a lower percentage of MEFV exon 10 mutations. Prolonged myalgia associated with PFMS is generally resistant to colchicine and shows a good response to corticosteroids. As FMF owing to MEFV exon 2 variants contribute to milder phenotype and better response to colchicine (9), our findings contribute to milder phenotype and better response to colchicine owing to multiple heterozygous MEFV exon 2 variants.


Late-onset familial Mediterranean fever (FMF); a subset with distinct clinical, demographic, and molecular genetic characteristics. Am J Med Genet 1999; 87: 30-35.

Competing interests: none declared.

References


